+100
ื”ื•ืจื“ื•ืช
ืกื™ื•ื•ื’ ืชื•ื›ืŸ
ื›ื•ืœื
ืฆื™ืœื•ื ืžืกืš
ืฆื™ืœื•ื ืžืกืš
ืฆื™ืœื•ื ืžืกืš
ืฆื™ืœื•ื ืžืกืš
ืฆื™ืœื•ื ืžืกืš

ืžื™ื“ืข ืขืœ ื”ืืคืœื™ืงืฆื™ื” ื”ื–ื•

TinySteps โ€“ ืขื ืฆืขื“ื™ื ืงื˜ื ื™ื ืœื—ื™ื™ ื™ื•ืžื™ื•ื ืคืขื™ืœื™ื
ืขื‘ื•ืจ ืื ืฉื™ื ืขื ืžื™ืืกื˜ื ื™ื” ื’ืจื‘ื™ืก (MG) ื•ื”ืคืจืขื•ืช ื‘ืกืคืงื˜ืจื•ื ื”ืื•ืคื˜ื™ ืฉืœ ื ื•ื™ืจื•ืžื™ืืœื™ื˜ื™ืก (NMOSD)

TinySteps ืคื•ืชื—ื” ื™ื—ื“ ืขื ืžื˜ื•ืคืœื™ื, ืคื™ื–ื™ื•ืชืจืคื™ืกื˜ื™ื ื•ื ื•ื™ืจื•ืœื•ื’ื™ื ื›ื“ื™ ืœื”ืฆื™ืข ืœืื ืฉื™ื ืขื ืžื™ืืกื˜ื ื™ื” ื’ืจื‘ื™ืก (MG) ื•ื”ืคืจืขื•ืช ื‘ืกืคืงื˜ืจื•ื ื”ืื•ืคื˜ื™ ืฉืœ ื ื•ื™ืจื•ืžื™ืืœื™ื˜ื™ืก (NMOSD) ื”ื–ื“ืžื ื•ืช ืœื”ื™ื•ืช ืคืขื™ืœื™ื ื‘ื—ื™ื™ ื”ื™ื•ืžื™ื•ื ืฉืœื”ื.
ื‘ืืคืœื™ืงืฆื™ื” ืชืžืฆืื• ืชืจื’ื™ืœื™ื ื”ืžื•ืชืืžื™ื ื‘ืžื™ื•ื—ื“ ืœืžื—ืœื” ื”ืžืชืื™ืžื”, ืชืจื’ื™ืœื™ื ื—ื™ื™ื ืœืงื—ืช ื‘ื”ื ื—ืœืง ื›ืœ ืฉื‘ื•ืขื™ื™ื ื•ืžื™ื“ืข ืฉื™ืžื•ืฉื™ ืขืœ ื”ืžื—ืœื” ื”ืžืชืื™ืžื”.

ืกืงื™ืจื” ื›ืœืœื™ืช ืฉืœ ื”ืคื•ื ืงืฆื™ื•ืช:
ื ื™ืชืŸ ืœืฉื™ืžื•ืฉ ืžื™ื™ื“ื™, ืœืœื ืชืฉืœื•ื ื•ืœืœื ื”ืจืฉืžื”
ืกืจื˜ื•ื ื™ ืชืจื’ื™ืœ ืงืฆืจื™ื ืฉื ื™ืชืŸ ืœื”ื•ืจื™ื“
ื ื™ืชืŸ ืœื”ืฉืชืžืฉ ื’ื ื‘ืžืฆื‘ ืœื ืžืงื•ื•ืŸ ืœืื—ืจ ื”ื”ื•ืจื“ื”
ื”ื“ื’ืฉืช ื”ืกืจื˜ื•ื ื™ื ืฉืืชื” ืื•ื”ื‘ ื‘ืžื™ื•ื—ื“ ื›ืžื•ืขื“ืคื™ื
ืคื•ื ืงืฆื™ื™ืช ื—ื™ืคื•ืฉ ืœืกืจื˜ื•ื ื™ื ื•ืžืืžืจื™ื
ืชืจื’ื™ืœื™ื ื—ื™ื™ื ื›ืœ ืฉื‘ื•ืขื™ื™ื
ืืชื” ื™ื›ื•ืœ ืœื”ืฆื™ื’ ืืช ืกืจื˜ื•ื ื™ ื”ืชืจื’ื™ืœื™ื ืฉื”ื•ืฉืœืžื• ื›ื”ืฆืœื—ื•ืช, ืื‘ืœ ืืชื” ืœื ื—ื™ื™ื‘
ืžืืžืจื™ื ืฉื›ื“ืื™ ืœื”ื›ื™ืจ
ื ื™ืชืŸ ืœื”ืคืขื™ืœ ืืช ืคื•ื ืงืฆื™ื™ืช ื”ืชื–ื›ื•ืจืช

ื›ืชื‘ ื•ื™ืชื•ืจ:
ืืคืœื™ืงืฆื™ื™ืช TinySteps ืื™ื ื” ืžื•ืฆืจ ืจืคื•ืื™. ื”ืชืจื’ื™ืœื™ื ื”ืžื•ืฆื’ื™ื ื›ืืŸ ืžืฉืžืฉื™ื ืจืง ื›ืชื‘ื ื™ืช ืœื”ื™ื•ืช ืคืขื™ืœ ื‘ื—ื™ื™ ื”ื™ื•ืžื™ื•ื. ื”ื ืื™ื ื ืžื—ืœื™ืคื™ื ื˜ื™ืคื•ืœ ืจืคื•ืื™ ืื• ื˜ื™ืคื•ืœื™.
ื ื™ืชืŸ ืœื‘ืฆืข ืืช ื”ืชืจื’ื™ืœื™ื ืจืง ืœืื—ืจ ื”ืชื™ื™ืขืฆื•ืช ื˜ื™ืคื•ืœื™ืช.
ื”ืชืžื™ื›ื” ื”ื˜ื›ื ื™ืช ืฉืœ ื”ืืคืœื™ืงืฆื™ื” ืฉืœื ื• ืื™ื ื” ืžื•ืกืžื›ืช ืœืชืช ืœืš ืขืฆื•ืช ื˜ื™ืคื•ืœื™ื•ืช.
ื‘ืžืงืจื” ืฉืœ ื”ื™ื“ืจื“ืจื•ืช ื‘ืžืฆื‘ ื”ื‘ืจื™ืื•ืชื™ ืื• ื”ื›ืื‘, ื™ืฉ ืœื”ืคืกื™ืง ืืช ื”ืชืจื’ื™ืœื™ื ื•ืœื”ืžืœื™ืฅ โ€‹โ€‹ืขืœ ื”ืขืจื›ื” ืจืคื•ืื™ืช.
Alexion Pharma Germany GmbH ืื™ื ื” ื ื•ืฉืืช ื‘ืื—ืจื™ื•ืช ืœืชืจื’ื™ืœื™ื ื”ืžื•ืฆื’ื™ื ื•ืœื›ืœ ื ื–ืง ืฉื ื’ืจื ื›ืชื•ืฆืื” ืžื›ืš.
ืขื“ื›ื•ืŸ ืื—ืจื•ืŸ ื‘ืชืืจื™ืš
1 ื‘ืื•ื’ืณ 2025

ืื‘ื˜ื—ืช ื ืชื•ื ื™ื

ื›ื“ื™ ืœืฉืžื•ืจ ืขืœ ื”ื‘ื˜ื™ื—ื•ืช ืฆืจื™ืš ืงื•ื“ื ื›ืœ ืœื”ื‘ื™ืŸ ืื™ืš ื”ืžืคืชื—ื™ื ืื•ืกืคื™ื ื•ืžืฉืชืคื™ื ืืช ื”ื ืชื•ื ื™ื ืฉืœืš. ื ื•ื”ืœื™ ืคืจื˜ื™ื•ืช ื”ื ืชื•ื ื™ื ื•ืื‘ื˜ื—ืช ื”ื ืชื•ื ื™ื ืขืฉื•ื™ื™ื ืœื”ืฉืชื ื•ืช ื‘ื”ืชืื ืœืฉื™ืžื•ืฉ, ืœืื–ื•ืจ ื•ืœื’ื™ืœ ื”ืžืฉืชืžืฉ. ื”ืžืคืชื— ืกื™ืคืง ืืช ื”ืžื™ื“ืข ื”ื–ื” ื•ื”ื•ื ืขืฉื•ื™ ืœืขื“ื›ืŸ ืื•ืชื• ืžื“ื™ ืคืขื.
ืœื ืžืชื‘ืฆืข ืฉื™ืชื•ืฃ ื ืชื•ื ื™ื ืขื ืฆื“ื“ื™ื ืฉืœื™ืฉื™ื™ื
ื”ื ืชื•ื ื™ื ืœื ืžื•ืฆืคื ื™ื
ืื™ ืืคืฉืจ ืœืžื—ื•ืง ืืช ื”ื ืชื•ื ื™ื

ืžื” ื—ื“ืฉ?

Erforderliche technische Aktualisierungen

ืชืžื™ื›ื” ื‘ืืคืœื™ืงืฆื™ื”

ืžื™ื“ืข ืขืœ ืžืคืชื—ื™ ื”ืืคืœื™ืงืฆื™ื”
AstraZeneca Pharmaceuticals LP
saravanakumar.v@astrazeneca.com
1800 Concord Pike Wilmington, DE 19897 United States
+91 90368 82892

โ€ซืขื•ื“ ืžื‘ื™ืช AstraZeneca Pharmaceuticals LPโ€Žโ€

ืืคืœื™ืงืฆื™ื•ืช ื“ื•ืžื•ืช